Insulet Corp. (NASDAQ:PODD) on Wednesday posted upbeat second-quarter results but lowered its full-year revenue guidance.
Adjusted earnings rose to $1.66 per share from $1.17 a year earlier, beating the analyst consensus estimate of $1.45. Revenue increased 23.5% year over year to $801.7 million, topping the Street estimate of $787.2 million.
“We delivered another quarter of broad-based growth, robust margin expansion, and positive free cash flow,” CEO Ashley McEvoy said.
For the third quarter, Insulet expects revenue of approximately $829.9 million to $844.0 million, below the analyst consensus estimate of $845.5 million.
The company also lowered its full-year 2026 revenue outlook to a range of approximately $3.25 billion to $3.30 billion from its prior forecast of $3.28 billion to $3.33 billion. The revised guidance also came in below the Wall Street estimate of $3.32 billion.
Insulet shares fell 1.4% to $131.37 in pre-market trading.
These analysts made changes to their price targets on Insulet following earnings announcement.
- Truist Securities analyst Richard Newitter downgraded the stock from Buy to Hold and lowered the price target from $210 to $153.
- JP Morgan analyst Robbie Marcus downgraded the stock from Overweight to Neutral and cut the price target from $275 to $152.
- Wells Fargo analyst Lawrence Biegelsen downgraded the stock from Overweight to Equal-Weight and slashed the price target from $255 to $144.
- BTIG analyst Marie Thibault downgraded the stock from Buy to Neutral.
Considering buying PODD stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments